巨细胞动脉炎中扩增的致病性调节性T细胞可被IL-6阻断治疗逆转
该研究将41例巨细胞动脉炎(GCA)患者分为活动期、激素缓解期和托珠单抗(TCZ)缓解期,比较外周血调节性T细胞(Treg)的频率、表型和功能。活动期GCA存在低增殖、富集IL-17+且表达Foxp3Δ2的Treg,抑制功能受损;TCZ治疗而非激素治疗可纠正这些异常,并增加活化Treg数量及CCR4、CTLA-4表达。
要点
- 活动期GCA的Treg低增殖且富集IL-17+ Treg,抑制功能受损。
- 活动期GCA的Treg高表达缺乏外显子2的Foxp3Δ2并共表达CD161。
- TCZ治疗可纠正Treg异常并增加活化Treg及CCR4、CTLA-4表达。
核心结论
- TCZ可能通过增加Treg增殖与活化、逆转活动期致病性Treg表型发挥治疗GCA的作用。
研究设计与样本
- 将41例GCA患者分为活动期(aGCA,n=11)、激素缓解期(rGCA-CS,n=19)和TCZ缓解期(rGCA-TCZ,n=11),并纳入健康对照比较外周血Treg的频率、表型和功能。
主要发现
- 活动期GCA患者Treg低增殖且富集IL-17分泌型Treg(IL-17+Tregs)。
- 活动期GCA患者Treg不成比例地表达缺乏外显子2的低功能Foxp3同工型(Foxp3Δ2),且Foxp3Δ2+ Treg较全长Foxp3+ Treg更常共表达CD161。
- 与健康对照相比,GCA来源的Treg抑制能力受损。
- TCZ治疗而非激素治疗可纠正活动期GCA中观察到的Treg异常。
- TCZ治疗增加活化Treg(CD45RA-Foxp3high)数量及Treg的CCR4和CTLA-4表达。
临床怎么用
- TCZ治疗GCA的疗效可能部分通过调节Treg增殖、活化及逆转致病性Treg表型实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their biology, we hypothesised that TCZ might modulate the Treg response in GCA. We therefore characterised the Treg compartment of patients with GCA treated with TCZ. METHODS: We classified 41 patients with GCA into three groups: active disease (aGCA, n=11), disease remission on corticosteroids (rGCA-CS, n=19) and disease remission on TCZ (rGCA-TCZ, n=11). Healthy controls (HCs) were included for comparison. We determined the frequency, phenotype and function of peripheral blood Tregs. RESULTS: Patients with aGCA demonstrated a hypoproliferating Treg compartment enriched in IL-17-secreting Tregs (IL-17+Tregs). Tregs in patients with aGCA disproportionally expressed a hypofunctional isoform of Foxp3 that lacks exon 2 (Foxp3Δ2). Foxp3Δ2-expressing Tregs coexpressed CD161, a marker commonly associated with the Th17 linage, significantly more often than full-length Foxp3-expressing Tregs. Compared with those of HCs, GCA-derived Tregs demonstrated impaired suppressor capacity. Treatment with TCZ, in contrast to CS therapy, corrected the Treg abnormalities observed in aGCA. In addition, TCZ treatment increased the numbers of activated Tregs (CD45RA-Foxp3high) and the Treg expression of markers of trafficking (CCR4) and terminal differentiation (CTLA-4). CONCLUSIONS: TCZ may exert its therapeutic effects in GCA by increasing the proliferation and activation of Tregs, and by reverting the pathogenic Treg phenotype seen during active disease.
引用
- Miyabe C, Miyabe Y, Strle K, et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2016. PMID: 27927642. doi:10.1136/annrheumdis-2016-210070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。